ORIC Pharmaceuticals, Inc.
NASDAQORIC Pharmaceuticals enters today's earnings report with nearly 30% of its free float sold short — a meaningful bearish overhang for a clinical-stage biotech that has rallied 8% over the past month. Short sellers are firmly committed heading into the print. SI % of FF has held in a tight band around 29–30% for the past six weeks, briefly touching 32% in early April before edging…
Snapshot as of 7 May 2026
ORIC Pharmaceuticals enters today's earnings report with nearly 30% of its free float sold short — a meaningful bearish overhang for a clinical-stage biotech that has rallied 8% over the past month. Short sellers are…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ORIC — free to start on ORTEX.
Sign up for free →Open ORIC on ORTEX